SCHEMBL3785887

SCHEMBL3785887

CN(C)c1ccc(N)c(-c2ccccc2N)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.52
L3MBTL1 Q9Y468 2/20 0.52
TDP1 Q9NUW8 3/20 0.41
ALOX15 P16050 2/20 0.41
CYP3A4 P08684 2/20 0.41
MAPK1 P28482 2/20 0.41
TP53 P04637 1/20 0.41
HSD17B10 Q99714 5/20 0.40
PDK2 Q15119 1/20 0.39
TSHR P16473 3/20 0.39
APAF1 O14727 1/20 0.39
MEN1 O00255 1/20 0.39
RAB9A P51151 1/20 0.39
KMT2A Q03164 1/20 0.39
PTK2B Q14289 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
CHEK1 O14757 1/20 0.38
NEK2 P51955 1/20 0.38
LIMK1 P53667 1/20 0.38
DYRK1A Q13627 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3790612 0.88 ALDH1A1 (0.52) ALDH1A1L3MBTL1TDP1ALOX15CYP3A4
SCHEMBL2774989 0.82 PSMB5 (0.49) ALDH1A1L3MBTL1TDP1ALOX15CYP3A4
SCHEMBL3793335 0.78 ALDH1A1 (0.58) ALDH1A1L3MBTL1TDP1ALOX15CYP3A4
SCHEMBL3787771 0.77 ALDH1A1 (0.52) ALDH1A1L3MBTL1TP53HSD17B10TSHR
SCHEMBL3790193 0.74 ALDH1A1 (0.56) ALDH1A1L3MBTL1TDP1ALOX15CYP3A4
SCHEMBL3791645 0.74 MAOA (0.42) ALDH1A1TDP1ALOX15CYP3A4MAPK1
SCHEMBL2313495 0.73 ALDH1A1 (0.52) ALDH1A1TDP1ALOX15CYP3A4MAPK1
SCHEMBL31361979 0.73 ALDH1A1 (0.52) ALDH1A1TDP1ALOX15CYP3A4MAPK1
SCHEMBL26030414 0.73 PDK2 (0.51) ALDH1A1L3MBTL1TDP1ALOX15CYP3A4
SCHEMBL7808585 0.73 KCNH2 (0.46) ALDH1A1TP53HSD17B10TSHRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2398795-A1 HETEROARYL SUBSTITUTED PYRIDAZINONE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2011-12-28 EP disclosed
WO-2010094762-A1 HETEROARYL SUBSTITUTED PYRIDAZINONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-08-26 WO disclosed
US-20100087680-A1 METHOD FOR PRODUCING BIARYL COMPOUND SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2010-04-08 US disclosed
EP-1914221-A1 PROCESS FOR PRODUCING BIARYL COMPOUND Sumitomo Chemical Company, Limited (JP) 2008-04-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087680-A1 METHOD FOR PRODUCING BIARYL COMPOUND NISCH, BLVRB, BBOX1 ALDH1A1 4339/4885L3MBTL1 3838/4885TDP1 4196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.